These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 27835900)
1. KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients. Kammerer S; Sokolowski A; Hackl H; Platzer D; Jahn SW; El-Heliebi A; Schwarzenbacher D; Stiegelbauer V; Pichler M; Rezania S; Fiegl H; Peintinger F; Regitnig P; Hoefler G; Schreibmayer W; Bauernhofer T Oncotarget; 2016 Dec; 7(51):84705-84717. PubMed ID: 27835900 [TBL] [Abstract][Full Text] [Related]
2. Critical evaluation of KCNJ3 gene product detection in human breast cancer: mRNA in situ hybridisation is superior to immunohistochemistry. Kammerer S; Jahn SW; Winter E; Eidenhammer S; Rezania S; Regitnig P; Pichler M; Schreibmayer W; Bauernhofer T J Clin Pathol; 2016 Dec; 69(12):1116-1121. PubMed ID: 27698251 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of KCNJ3 gene splice variants affects vital parameters of the malignant breast cancer cell line MCF-7 in an opposing manner. Rezania S; Kammerer S; Li C; Steinecker-Frohnwieser B; Gorischek A; DeVaney TT; Verheyen S; Passegger CA; Tabrizi-Wizsy NG; Hackl H; Platzer D; Zarnani AH; Malle E; Jahn SW; Bauernhofer T; Schreibmayer W BMC Cancer; 2016 Aug; 16():628. PubMed ID: 27519272 [TBL] [Abstract][Full Text] [Related]
4. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre. Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab. Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689 [TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors for Luminal B-like Breast Cancer. Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of the G-protein inwardly rectifying potassium channel 1 (GIRK1) in primary breast carcinomas correlates with axillary lymph node metastasis. Stringer BK; Cooper AG; Shepard SB Cancer Res; 2001 Jan; 61(2):582-8. PubMed ID: 11212253 [TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825 [TBL] [Abstract][Full Text] [Related]
9. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950 [TBL] [Abstract][Full Text] [Related]
10. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? Falck AK; Fernö M; Bendahl PO; Rydén L World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203 [TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of HOTAIR expression is restricted to ER-negative breast cancers. Gökmen-Polar Y; Vladislav IT; Neelamraju Y; Janga SC; Badve S Sci Rep; 2015 Mar; 5():8765. PubMed ID: 25739705 [TBL] [Abstract][Full Text] [Related]
12. High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer. Li Y; Qin J; Wu J; Dai X; Xu J Breast Cancer Res Treat; 2020 Jul; 182(1):35-46. PubMed ID: 32424721 [TBL] [Abstract][Full Text] [Related]
13. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M; Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859 [TBL] [Abstract][Full Text] [Related]
16. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556 [TBL] [Abstract][Full Text] [Related]
17. ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer. Ma B; Ma Q; Jin C; Wang X; Zhang G; Zhang H; Seeger H; Mueck AO Int J Clin Exp Pathol; 2015; 8(10):13279-83. PubMed ID: 26722530 [TBL] [Abstract][Full Text] [Related]
18. Cloning and characterisation of GIRK1 variants resulting from alternative RNA editing of the KCNJ3 gene transcript in a human breast cancer cell line. Wagner V; Stadelmeyer E; Riederer M; Regitnig P; Gorischek A; Devaney T; Schmidt K; Tritthart HA; Hirschberg K; Bauernhofer T; Schreibmayer W J Cell Biochem; 2010 Jun; 110(3):598-608. PubMed ID: 20512921 [TBL] [Abstract][Full Text] [Related]
19. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer. Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993 [TBL] [Abstract][Full Text] [Related]
20. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast. Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]